New drug combo shows promise for tough lung cancers
NCT ID NCT03600701
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 27 times
Summary
This study tests whether combining two drugs—atezolizumab (an immunotherapy that helps the immune system attack cancer) and cobimetinib (a targeted therapy that blocks cancer growth signals)—can shrink tumors or slow disease in people with advanced non-small cell lung cancer that no longer responds to standard immunotherapy. About 51 adults with metastatic or recurrent lung cancer will receive both drugs. The main goal is to see how many patients have a durable response (tumor shrinkage lasting at least 6 months).
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
Lebanon, New Hampshire, 03756, United States
-
Emory Saint Joseph's Hospital
Atlanta, Georgia, 30342, United States
-
Emory University Hospital Midtown
Atlanta, Georgia, 30308, United States
-
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
Hayworth Cancer Center
High Point, North Carolina, 27262, United States
-
MedStar Georgetown University Hospital
Washington D.C., District of Columbia, 20007, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
NYP/Weill Cornell Medical Center
New York, New York, 10065, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
-
UC San Diego Moores Cancer Center
La Jolla, California, 92093, United States
-
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, 35233, United States
-
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104, United States
-
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania, 15232, United States
-
University of Virginia Cancer Center
Charlottesville, Virginia, 22908, United States
-
Wake Forest University Health Sciences
Winston-Salem, North Carolina, 27157, United States
-
Wake Forest University at Clemmons
Clemmons, North Carolina, 27012, United States
-
Wayne State University/Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
Conditions
Explore the condition pages connected to this study.